Rosacea is a chronic and progressive skin condition characterized by episodes of remission and exacerbations of its many cutaneous symptoms, including flushing, facial erythema, telangiectasia, edema, papules, pustules, ocular lesions, and rhinophyma.
In September, the White House issued an executive order that the federal government will increase its efforts to combat antibiotic resistance nationally and internationally, and that the Centers for Disease Control and Prevention (CDC) “estimates that annually at least two million illnesses and 23,000 deaths are caused by antibiotic-resistant bacteria in the United States alone.”
Previous studies have shown that rosacea and acne have a significant impact on patients’ health-related quality of life (QOL), manifested as shame, embarrassment, anxiety, stress, social phobia, depression, as well as social and employment discrimination.
The pathogenesis of rosacea—a chronic inflammatory disorder that is characterized by facial papules, pustules, and persistent erythema—is multifactorial. Many factors are believed to activate neurovascular and immune responses, leading to inflammation that results in “flares.” One of these components is believed to be infestation with the microorganisms Demodex folliculorum and Demodex brevis, which are skin mites.
The pathogenesis of rosacea is multifactorial: one component is believed to be infestation with microorganisms, the skin mites Demodex folliculorum and Demodex brevis. A compound, ivermectin 1% cream, which is currently under review by the US Food and Drug Administration (FDA), is the first agent to target an underlying cause of rosacea, infestation with the Demodex skin mites. If approved by the FDA, this new compound will be the first medication to address a key component of papulopustular rosacea.
Linda F. Stein Gold, MD, Director of Dermatology Research at Henry Ford Health System, Detroit, MI, has many years of clinical and research experience in the treatment of patients with skin disorders. She spoke with American Health & Drug Benefits about the current status of the treatment of patients with rosacea, suggesting that new treatments currently in late development are expected to improve outcomes.
A novel compound currently in development, ivermectin 1% cream, targets the underlying cause of papulopustular rosacea (a prevalent type of rosacea), which is associated with an infestation of Demodex folliculorum, a skin mite that harbors the bacteria linked to rosacea.
Several studies presented at the 2014 American Academy of Dermatology (AAD) annual meeting sought to characterize the emotional burden of rosacea, as well as what treatments are being prescribed, and how much they are costing the healthcare system.
Rosacea affects an estimated 16 million US adults, but its underlying cause remains unclear. Studies presented at the 2014 American Academy of Dermatology (AAD) annual meeting offered some insights about the mechanism of inflammation, suggesting that doxycycline 40 mg modified release (MR) may improve the symptoms of papulopustular rosacea by modulating factors that augment inflammation. Other investigators reported treatment success for rosacea with novel agents.
Rosacea is a chronic inflammatory skin disorder with multiple signs and symptoms. Although one symptom or subtype of rosacea may be predominant in a given individual, another person with the same condition may have different manifestations. The treatment of rosacea is optimized when it is individualized.
Page 1 of 3
Results 1 - 10 of 25
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME